Abstract: The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.

Abstract: A method for the determination and individual characterization of particles by means of at least two different detectable probes in a sample is proposed, wherein the particles, especially molecules or molecular aggregates, have at least one binding site, preferably a multitude of binding sites, for at least one of said at least two different detectable probes; said at least two different detectable probes are present in the sample; a measure of the number of bound probes and the mutual ratio of bound probes are established by determining particles; said determining being effected on the basis of single particles.

Abstract: A method for the identification of substances for influencing aggregations comprising the following steps: a) combining at least one aggregate having a first detectable function and at least one monomer having a second detectable function, wherein said at least one monomer has an affinity for said at least one aggregate, in the presence of a potentially aggregation-influencing substance; b) determining a degree of labeling of the aggregates, the degree of labeling being a measure of the number and proportion of the detectable functions bound.

Abstract: A method for the diagnostic detection of diseases associated with protein depositions (pathological protein depositions) by measuring an association of substructures of the pathological protein depositions, structures forming pathological protein depositions, structures corresponding to pathological protein depositions and/or pathological protein depositions as a probe; to substructures of the pathological protein depositions structures forming pathological protein depositions, structures corresponding to pathological protein deposition and/or pathological protein depositions as targets; characterized in that the target is detected in liquid phase wherein, in the case of detecting Alzheimer's disease, the liquid phase is obtained from body fluids or is itself a body fluid; with the proviso that the association of the probe to the target is measured before self-aggregation of the probe predominates.

Abstract: A method for the diagnostic detection of diseases associated with protein depositions (pathological protein depositions) by measuring an association of substructures of the pathological protein depositions, structures forming pathological protein depositions, structures corresponding to pathological protein depositions and/or pathological protein depositions as a probe; to substructures of the pathological protein depositions, structures forming pathological protein depositions, structures corresponding to pathological protein depositions and/or pathological protein depositions as targets; characterized in that the target is detected in liquid phase wherein, in the case of detecting Alzheimer's disease, the liquid phase is obtained from body fluids or is itself a body fluid; with the proviso that the association of the probe to the target is measured before self-aggregation of the probe predominates.

Abstract: The invention relates to a method for detecting reactions and conformational changes of analytes in a sample by coincidence analysis, as follows: the sample is marked with at least two different fluorescent dyes and then illuminated with at least one laser in order to stimulate the emission of fluorescence; the fluorescence signals are detected by at least two detection units and each signal is broken down into any simultaneous time segments with the desired time slot widths; the number of signals contained in at least one time segment and/or the time intervals between signals in the time segments are detected; a coincidence analysis of the data detected is carried out for at least one time segment of the first detection unit with at least one isochronous time segment of the second detection unit; statistics are produced showing the results of the coincidence analysis and/or the results are subjected to a threshold value analysis, and these statistics or a combination of more statistics are evaluated for the